Understanding dengue pathogenesis: Implications for vaccine design

Bulletin of the World Health Organization

Volumn 83, Issue 4, 2005, Pages 308-314

  Stephenson, John R ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antibody dependent enhancement immunology; Cross reactions; Dengue hemorrhagic fever immunology; Dengue virus pathogenicity immunology; Review literature; T lymphocytes immunology; Vaccines, Attenuated

Indexed keywords

CHIMERIVAX DENGUE; DENGUE VACCINE; NONSTRUCTURAL PROTEIN 3; PROTEIN NS1; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

DENGUE FEVER; VACCINATION;

ANTIBODY RESPONSE; CELLULAR IMMUNITY; DENGUE; DENGUE SHOCK SYNDROME; DENGUE VIRUS; DRUG DESIGN; EPIDEMIOLOGICAL DATA; GENOTYPE; HUMAN; IMMUNE RESPONSE; INFECTION SENSITIVITY; PATHOGENESIS; PROTEIN INDUCTION; PUBLIC HEALTH SERVICE; REVIEW; SHOCK; T LYMPHOCYTE; VIREMIA; VIRUS GENE; VIRUS PATHOGENESIS; VIRUS RECOMBINANT;

ANTIBODY-DEPENDENT ENHANCEMENT; CROSS REACTIONS; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; DEVELOPING COUNTRIES; DRUG DESIGN; HUMANS; RESEARCH SUPPORT; SAFETY; T-LYMPHOCYTES; VIRAL VACCINES; WORLD HEALTH;

EID: 17244375118     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Gubler DJ. Dengue and dengue haemorrhagic fever: its history and resurgence as a global public health problem. In: Gubler DJ, Kuno G, editors. Dengue and dengue haemorrhagic fever. New York: CAB International; 1997. p. 1-22.
2. Halstead SB. Dengue. Current Opinion in Infectious Diseases 2002;15:471-6.
3. Stephenson JR. Flavivirus vaccines. Vaccine 1998;6:471-80.
4. Monath TP, Heinz FX. Flaviviruses. In: Fields BN, Knipe DM, Howley PM, editors. Fields' Virology, 3rd edition. Philadelphia: Lippincott & Raven; 1996. p. 961-1034.
5. McBride WJH, Bielefeldt-Ohmann H. Dengue viral infections; pathogenesis and epidemiology. Microbes and Infections 2000;2:1041-50.
6. Guzman MG, Kouri G. Dengue: an update. Lancet Infectious Diseases 2002;2:33-42.
7. Halstead SB. Immune enhancement of viral infection. Progress in Allergy 1982;31:301-64.
8. Halstead SB. Neutralisation and antibody-dependent enhancement of dengue viruses. Advances in Virus Research 2003;60:421-67.
9. Gollins SW, Porterfield JS. A new mechanism for the neutralisation of enveloped viruses by anti-viral antibody. Nature 1986;321:244-6.
10. Cardosa MJ, Porterfield JS, Gordon S. Complement receptor mediates enhanced flavivirus replication in macrophages. Journal of Experimental Medicine 1983;158:258-63.
11. Peiris JSM, Porterfield JS. Antibody-dependent enhancement: its antigenic specificity in relation to Togaviridae. Journal of General Virology 1982;58:291-6.
12. Phillpotts RJ, Stephenson JR, Porterfield JS. Antibody dependent enhancement of TBEV infectivity. Journal of General Virology 1985;66:1831-7.
13. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitaya S, Suntayakorn S, et al. Dengue viraemia titre, antibody response pattern and virus serotype correlate with disease severity. Journal of Infectious Diseases 2000;181:2-9.
14. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue haemorrhagic fever. American Journal of Tropical Medicine and Hygiene 1989;40:444-51.
15. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. Journal of Infectious Diseases 2004;189:990-1000.
16. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. Journal of Infectious Diseases 2000;182:2-9.
17. Guzman MG, Kouri G, Valdes L, Bravo J, Alvarez M, Vazques S, et al. Epidemiologic studies on dengue in Santiago de Cuba. American Journal of Epidemiology 2000;152:793-9.
18. Vaughn DW. Invited commentary: dengue lessons from Cuba. American Journal of Epidemiology 2000;152:800-3.
19. Kawaguchi I, Sasaki A, Boots M. Why are dengue virus serotypes so distantly related? Enhancement and limiting serotype similarity between dengue virus strains. Proceedings of the Royal Society London B 2003;270:2241-7.
20. Holmes EC, Twiddy SS. The origin, emergence and evolutionary genetics of dengue virus. Infection, Genetics and Evolution 2003;3:19-28.
21. Rothman AL. Immunology and immunopathogenesis of dengue disease. Advances in Virus Research 2003;60:397-419.
22. Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A. Inhibition of interferon signalling by dengue virus. Proceedings of the National Academy of Science USA 2003;100:14333-8.
23. Mashimo T, Lucas M, Simon-Chazottes D, Frenkiel M, Montagutelli X, Ceccaldi PE, et al. A nonsense mutation in the gene encoding 2′-5′-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proceedings of the National Academy of Science USA 2002;99:11311-6.
24. Rothman AL, Ennis FA. Immunopathogenesis of dengue haemorrhagic fever. Virology 1999;257:1-6.
25. Green S, Vaughn DW, Kalayanarooj S, Nimmannitaya S, Suntayakorn S, Nisalak A, et al. Early immune activation in acute dengue is related to development of plasma leakage and disease severity. Journal of Infectious Diseases 1999;179:755-62.
26. Chaturvedi UC, Argwal R, Elbishbishi EA, Mustafa AS. Cytokine cascade in dengue haemorrhagic fever: implications for pathogenesis. FEMS Immunology and Medical Microbiology 2000;28:183-8.
27. Zivna I, Green S, Vaughn DW, Kalayanarooj S, Stephens S, Chandanayingyong D, et al. T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. Journal of Immunology 2002;168:5959-65.
28. Loke H, Bethell DB, Phuong CX, Dung M, Schneider J, White NJ, et al. Strong HLA class I-restricted T cell responses in dengue haemorrhagic fever: a double edged sword? Journal of Infectious Diseases 2001;184:1369-73.
29. Scott RM, Eckels KH, Bancroft WH, Summers PL, McCown JM, Anderson JH, et al. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status. Journal of Infectious Diseases 1983;148:1055-60.
30. Mongkolsapaya J, Dejnirattisai W, Xu X, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue haemorrhagic fever. Nature Medicine 2003;9:921-7.
31. Fazekas de St G, Webster RG. Disquisitions of original antigen sin. I. Evidence in man. Journal of Experimental Medicine 1966;124:331-45.
32. Hughes AL. Evolutionary change of predicted cytotoxic T cell epitopes of dengue virus. Infection, Genetics and Evolution 2001;1:123-30.
33. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. American Journal of Tropical Medicine and Hygiene 1988;38:172-89.
34. King NJC, Shresthra B, Kesson AM. Immune modulation by flaviviruses. Advances in Virus Research 2003;60:121-55.
35. Huang Y-H, Lei H-Y, Liu H-S, Lin Y-S, Chen S-H, Liu C-C, et al. Tissue plasminogen activator induced by dengue virus infection of human endothelial cells. Journal of Medical Virology 2003;70:610-6.
36. Lin C-F, Lei H-Y, Shiau A-L, Liu C-C, Liu H-S, Yeh T-M, et al. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. Journal of Medical Virology 2003;69:82-90.
37. Falconar AKI. The dengue virus non-structural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human epithelial cells: potential implication in haemorrhagic fever pathogenesis. Archives of Virology 1997;142:897-916.
38. Baeuerle PA, Henkel T. Function and activation of NF- Kappa B in the immune system. Annual Reviews in Immunology 1994;12:141-79.
39. Halstead SB, Deen J. The future of dengue vaccines. Lancet 2002;360:1243-5.
40. Jacobs M, Young P. Dengue vaccines: preparing to roll back dengue. Current Opinion in Investigational Drugs 2003;4:168-71.
41. Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet 2004;363:2073-5.
42. Stephenson JR. Recombinant defective adenoviruses as novel vaccines for the Flaviviridae. Clinical and Diagnostic Virology 1998;10:187-94.
43. Monath TP. Japanese encephalitis vaccines: current vaccines and future prospects. Current Topics in Microbiology and Immunology 2002;267:105-38.
44. Jaiswal S, Khanna N, Swaminathan S. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. Journal of Virology 2003;77:12907-13.
45. Jacobs SC, Wilkinson GWG, Stephenson JR. High level expression of TBEV NS1 protein by using an adenovirus-based vector: protection elicited in a murine model. Journal of Virology 1992;66:2086-95.
46. Lin YL, Chen LK, Liao CL, Yeh CT, Ma SH, Chen JL, et al. DNA immunization with Japanese encephalitis virus non-structural protein NS1 elicits protective immunity in mice. Journal of Virology 1998;72:191-200.
47. Morozova OV, Maksimova TG, Bakhvalova VN. Tick-borne encephalitis virus NS3 gene expression does not protect mice from homologous viral challenge. Viral Immunology 1999;12:277-80.
48. Alcon S, Talarmin A, Debruyne M, Falconar A, Deubel V, Flamand M. Enzyme-linked immunosorbent assay specific to Dengue virus type 1 non-structural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. Journal of Clinical Microbiology 2002;40:376-81.
49. Almond J, Clemens J, Engers H, Halstead SB, Khiem HB, Pablos-Mendes A, et al. Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City. Vaccine 2002;20:3043-6.